Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Astra gets Wilson disease bonus
ALXN1840 could challenge older copper chelators, but gene therapies are coming.
Aldeyra eyes the future
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
Bausch boosted ahead of eye spin-off
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Persistence pays off for Kala
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
Corporate and regulatory developments over the Christmas period
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
